首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   148816篇
  免费   11950篇
  国内免费   4978篇
耳鼻咽喉   2098篇
儿科学   2294篇
妇产科学   2192篇
基础医学   19595篇
口腔科学   3115篇
临床医学   16075篇
内科学   24781篇
皮肤病学   3706篇
神经病学   8310篇
特种医学   6851篇
外国民族医学   22篇
外科学   16730篇
综合类   14373篇
现状与发展   18篇
一般理论   35篇
预防医学   10347篇
眼科学   3420篇
药学   15179篇
  80篇
中国医学   5598篇
肿瘤学   10925篇
  2024年   282篇
  2023年   1542篇
  2022年   4072篇
  2021年   5939篇
  2020年   3876篇
  2019年   3863篇
  2018年   4364篇
  2017年   3891篇
  2016年   4299篇
  2015年   6539篇
  2014年   8107篇
  2013年   9011篇
  2012年   13282篇
  2011年   13115篇
  2010年   8772篇
  2009年   7430篇
  2008年   9475篇
  2007年   8754篇
  2006年   8050篇
  2005年   7119篇
  2004年   5524篇
  2003年   4887篇
  2002年   4211篇
  2001年   3334篇
  2000年   2851篇
  1999年   2250篇
  1998年   950篇
  1997年   863篇
  1996年   681篇
  1995年   597篇
  1994年   518篇
  1993年   356篇
  1992年   772篇
  1991年   673篇
  1990年   636篇
  1989年   576篇
  1988年   545篇
  1987年   487篇
  1986年   385篇
  1985年   347篇
  1984年   281篇
  1983年   231篇
  1982年   140篇
  1981年   137篇
  1980年   117篇
  1979年   215篇
  1978年   155篇
  1977年   108篇
  1975年   112篇
  1974年   120篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Moderate sedatives have been increasingly used to improve patient comfort during flexible bronchoscopy (FB). However, routine use of moderate sedation during FB is controversial because its efficacy and safety are not well established.This study aims to evaluate the efficacy and safety of moderate sedation during FB.A search was made of Medline, EMBASE, and the Cochrane Library to May 2014.Randomized controlled trials (RCTs) and quasi-RCTs were included.The main analysis was designed to examine the efficacy of moderate sedation during FB in sedation than no-sedation.The willingness to repeat FB was significantly more in sedation than no-sedation (odds ratio [OR] 2.30; 95% confidence interval [CI] 1.11–4.73; P = 0.02; I2 = 22.5). The duration of FB was shorter in sedation group than no-sedation group (standardized mean difference [SMD] −0.21; 95% CI −0.38 to −0.03; P = 0.02; I2 = 78.3%). Event of hypoxia was not significantly different between sedation and no-sedation groups (OR 0.86; 95% CI 0.42–1.73; P = 0.67; I2 = 0%). The SpO2 during procedure was not different between sedation and no-sedation groups (SMD −0.14; 95% CI −0.37 to 0.08; P = 0.21; I2 = 49.9%). However, in subgroup analysis without supplemental oxygen, the SpO2 was significantly lower in sedation than no-sedation group (SMD −0.45; 95% CI −0.78 to −0.11; P = 0.01; I2 = 0.0%).According to this meta-analysis, moderate sedation in FB would be useful in patients who will require repeated bronchoscopies as well as safe in respiratory depression. To our knowledge, although the various sedative drugs are already used in the real field, this analysis was the first attempt to quantify objective results. We anticipate more definite and studies designed to elucidate standardized outcomes for moderate sedation in FB.  相似文献   
13.
内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。  相似文献   
14.
背景 恶性肿瘤给家庭、社会带来了沉重的医疗、经济负担,极易导致部分家庭“因病致贫”或放弃治疗,目前相关研究多集中于单一病种、分散地域的研究,仍缺乏对于全国范围与多病种恶性肿瘤住院费用变化及结构构成的考量。目的 分析2013-2017年我国4种恶性肿瘤住院费用水平以及影响住院费用的主要项目和结构变动情况,为控制医疗费用上涨、深化新医改提供参考依据。方法 本研究数据来源于《2014中国卫生和计划生育统计年鉴》《2015中国卫生和计划生育统计年鉴》《2016中国卫生和计划生育统计年鉴》《2017中国卫生和计划生育统计年鉴》以及《2018中国卫生健康统计年鉴》,样本跨度为2013-2017年。统计“30种疾病人均住院费用”中的胃恶性肿瘤、肺恶性肿瘤、食管恶性肿瘤以及膀胱恶性肿瘤的数据,4种恶性肿瘤的人均住院费用包括药费、检查费、治疗费、手术费和手术材料费。2019年4-8月,采用结构变动度法分析我国2013-2017年4种恶性肿瘤的住院费用的结构变动情况〔结构变动值(VSV)、结构变动度(DSV)、结构变动贡献率〕。结果 2013-2017年,4种恶性肿瘤的人均住院费用逐年上升,其中胃恶性肿瘤的人均住院费用始终最高,且肺恶性肿瘤的人均住院费用上升幅度最大。2013-2017年,在4种恶性肿瘤住院各项费用的占比中,药费占比最高且总体逐年下降。从4种恶性肿瘤住院各项费用的实际变化来看,药费在2013-2014年有所上升,2014-2017年逐年下降;检查费在2013-2014年下降,2014-2017年缓慢上升;手术费与手术材料费在2013-2017年逐年上升。2013-2017年,在4种恶性肿瘤住院各项费用中均是药费的VSV最大;4种恶性肿瘤药费、检查费的VSV均呈负向变化,手术费和手术材料费的VSV均呈正向变化,治疗费的VSV增减均不明显。2013-2017年,4种恶性肿瘤住院费用的DSV从大到小依次为肺恶性肿瘤、胃恶性肿瘤、食管恶性肿瘤、膀胱恶性肿瘤。2013-2017年,4种恶性肿瘤住院各项费用中均是药费的结构变动贡献率最大,治疗费的结构变动贡献率最小;除药费外,胃恶性肿瘤、肺恶性肿瘤住院各项费用中均是手术材料费和手术费的结构变动贡献率次之,食管恶性肿瘤住院各项费用中手术费、检查费的结构变动贡献率次之,膀胱恶性肿瘤住院各项费用中检查费、手术材料费的结构变动贡献率次之。结论 2013-2017年我国4种恶性肿瘤手术费的结构变动贡献率虽然较为理想,但药费、治疗费仍是住院费用结构的重点调整对象;同时为有效降低恶性肿瘤的人均住院费用,应当加强控制手术材料费与检查费;而胃恶性肿瘤与肺恶性肿瘤患者的疾病经济负担严重,若要缓解应加强疾病的早期预防与住院费用管控。  相似文献   
15.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
16.
Direct peroral cholangioscopy (POC) using an ultra‐slim upper endoscope is one modality of POC for intraductal endoscopic evaluation and treatment of the bile duct. Choledochoduodenostomy (CDS) is one modality of biliary bypass surgery that provides a new route to the bile duct. We carried out direct POC using an ultra‐slim upper endoscope without the use of accessories in 10 patients (four sump syndromes, three bile duct strictures and three intrahepatic duct stones) previously undergoing surgical CDS. Direct POC was successful in all patients. The use of an intraductal balloon catheter was required in one patient for advancement of the endoscope into the bile duct. Distal bile ducts with sump syndromes were cleared using baskets and water irrigation under direct POC. Cholangiocarcinoma was diagnosed in one patient with hilar bile duct stricture after cholangioscopic evaluation and a targeting forceps biopsy under direct POC. Intrahepatic duct stones were successfully extracted after intraductal fragmentation under direct POC. Oozing bleeding occurred during intraductal lithotripsy but stopped spontaneously. Direct POC using an ultra‐slim upper endoscope without the assistance of accessories can easily be carried out in patients undergoing CDS.  相似文献   
17.
18.
19.
ABSTRACT

Purpose

Work-related eye injuries have been reported with a variety of epidemiologic and clinical characteristics. We aimed to identify epidemiologic characteristics of work-related eye injuries and risk factors associated with severe injury in a large metropolitan city.  相似文献   
20.
Abstract

Objective

Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号